Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Share-based Compensation (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Share-based Compensation for 4 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation changed 0.3% to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.4 million through Dec 2025, down 8.03% year-over-year, with the annual reading at $44.4 million for FY2025, 8.03% down from the prior year.
  • Share-based Compensation for Q4 2025 was $11.1 million at Day One Biopharmaceuticals, up from $9.6 million in the prior quarter.
  • The five-year high for Share-based Compensation was $13.0 million in Q2 2024, with the low at $5.6 million in Q2 2022.
  • Average Share-based Compensation over 4 years is $10.0 million, with a median of $10.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 68.3% in 2023, then dropped 17.25% in 2025.
  • Over 4 years, Share-based Compensation stood at $6.8 million in 2022, then surged by 58.22% to $10.8 million in 2023, then grew by 2.07% to $11.0 million in 2024, then rose by 0.3% to $11.1 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $11.1 million, $9.6 million, and $10.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.